Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal Watch: Bristol Doubles Down On Five Prime, Roche Continues Diversifying

Executive Summary

Roche buyout of California biotech Adheron will strengthen its pipeline in rheumatoid arthritis and fibrosis. Lilly keeps busy, expanding an immuno-oncology collaboration with China's Innovent and acquiring a Phase III intranasal hypoglycemia candidate from Locemia.

Advertisement

Related Content

Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
Roche’s Ocrelizumab Poised To Seize Primary Progressive MS Opportunity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register